- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01207752
The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction
March 16, 2021 updated by: Jerry R. Paugh, OD, PhD, Southern California College of Optometry at Marshall B. Ketchum University
Evaluation of the Efficacy of an Ocular Emulsion on the Signs and Symptoms of Meibomian Gland Dysfunction
The aim of this study will be to determine the efficacy of this novel, lipid-containing artificial tear on the signs and symptoms of meibomian gland disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
69
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Fullerton, California, United States, 92831
- Eye Care Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Schein symptom score (all 6 questions) of greater than 5,
- evidence of MGD changes in both eyes (i.e.,
- lower eyelid secretion quality score greater than 1.0 (0 - 3 scale) OR gland dropout score greater than 1.0 (i.e., greater than 25% of entire lower eyelid) as demonstrated by meiboscopy, and corneal staining of grade 4.0 or greater (0 - 20 scale).
Exclusion Criteria:
- contact lens wear, use of topical ocular medication other than artificial tears (use of Restasis is specifically excluded),
- unstable systemic medication use (i.e., anti-histamines, steroids, etc.), recent (within 6 months of study start) ocular trauma or surgery,
- diabetes, aqueous deficient dry eye (defined as a Schirmer I value (without anesthetic) of < 5 mm of wetting in 5 minutes in either eye), and use of punctal plugs.
-Subjects taking omega 3 fatty acid supplements for dry eye can be included so long as their intake is stable for the prior six months and they meet the inclusion criteria above. -
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Systane Balance
Artificial tear emulsion
|
Artificial tear emulsion drop
|
Active Comparator: Optive Lubricant Eye Drops
Artificial tear
|
Artificial tear eye drop
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tear Film Breakup Time
Time Frame: Measured 2 hours after in-office administration of a single drop of test solution
|
time in seconds to observer a dark spot in the tear film
|
Measured 2 hours after in-office administration of a single drop of test solution
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2010
Primary Completion (Actual)
July 1, 2011
Study Completion (Actual)
July 1, 2011
Study Registration Dates
First Submitted
September 21, 2010
First Submitted That Met QC Criteria
September 22, 2010
First Posted (Estimate)
September 23, 2010
Study Record Updates
Last Update Posted (Actual)
April 9, 2021
Last Update Submitted That Met QC Criteria
March 16, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SCCO 10-6
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Meibomian Gland Dysfunction
-
Hovione Scientia LimitedCompletedMeibomian Gland Dysfunction | MGD-Meibomian Gland DysfunctionUnited States
-
University of WaterlooCompletedMeibomian Gland Dysfunction (MGD)Canada
-
Aier School of Ophthalmology, Central South UniversityUnknownMeibomian Gland Massage is Important to Delay the Development of Meibomian Gland DysfunctionChina
-
Second Affiliated Hospital, School of Medicine,...Aier Eye Hospital, WuhanCompletedMGD-Meibomian Gland DysfunctionChina
-
Barzilai Medical CenterCompletedMGD-Meibomian Gland DysfunctionIsrael
-
Singapore National Eye CentreNational University, SingaporeCompleted
-
Johnson & Johnson Surgical Vision, Inc.CompletedCataracts | Meibomian Gland Dysfunction (MGD)United States
-
Azura OphthalmicsThe University of New South WalesCompletedMeibomian Gland Dysfunction (MGD) | Contact Lens Discomfort (CLD)Australia
-
Zhongnan HospitalRecruitingDry Eye | MGD-Meibomian Gland DysfunctionChina
-
Zhongnan HospitalRecruitingDry Eye | Positron-Emission Tomography | MGD-Meibomian Gland DysfunctionChina
Clinical Trials on Systane Balance
-
Horus PharmaNot yet recruitingDry Eye | Meibomian Gland Dysfunction
-
Alcon ResearchCompletedDry Eye Syndrome
-
University of the Incarnate WordCompletedDry Eye Syndromes | Meibomian Gland Dysfunction
-
Laboratorios Sophia S.A de C.V.Completed
-
Scripps Poway Eyecare and OptometrySengiRecruiting
-
Ophthalmic Consultants of ConnecticutUnknown
-
Alcon ResearchCompletedDry Eye Syndrome | Lipid Deficiency
-
Alcon ResearchCompleted